Neisseria gonorrhoeae strain with reduced susceptibilities to extended- spectrum cephalosporins

Emerging Infectious Diseases

Volumn 20, Issue 7, 2014, Pages 1211-1213

  Nguyen, Duylinh ^a   Gose, Severin ^a   Castro, Lina ^a   Chung, Kathleen ^a   Bernstein, Kyle ^a   Samuel, Michael ^b   Bauer, Heidi ^b   Pandori, Mark ^a  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CULTURE MEDIUM; EPSILOMETER TEST; GENE FREQUENCY; GONOCOCCAL URETHRITIS; GONORRHEA; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NONHUMAN; PHENOTYPE; TREATMENT FAILURE; UNITED STATES; DISEASE PREDISPOSITION; DRUG EFFECTS; GENOTYPE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CALIFORNIA; CEFTRIAXONE; CEPHALOSPORINS; DISEASE SUSCEPTIBILITY; GENOTYPE; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 84902792049     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2007.131396     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention (CDC). CDC Grand Rounds: the growing threat of multidrug-resistant gonorrhea. MMWR Morb Mortal Wkly Rep. 2013;62:103-6.
2. Al-Fouzan A, Al-Mutairi N. Overview of incidence of sexually transmitted diseases in Kuwait. Clin Dermatol. 2004;22:509-12. http://dx.doi.org/10.1016/j.clindermatol.2004.07.002
3. Ndowa F, Lusti-Narasimhan M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod Health Matters. 2012;20:76-82. http://dx.doi. org/10.1016/S0968-8080(12)40653-X
4. Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis. 2013;13:40. http://dx.doi.org/10.1186/1471-2334-13-40
5. Tanaka M, Nakayama H, Huruya K, Konomi I, Irie S, Kanayama A, et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents. 2006;27:20-6. Epub 2005 Nov 28. http://dx.doi.org/10.1016/j.ijantimicag.2005.08.021
6. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309:163-70. http:// dx.doi.org/10.1001/jama.2012.176575
7. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 2010;15:pii: 19721.
8. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, et al.; GRASP collaborative group. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis. 2013;13:762-8. Epub 2013 Jun 11. http://dx.doi.org/10.1016/S1473-3099(13)70143-9
9. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother. 2013;68:1267-70. Epub 2013 Feb 14. http://dx.doi.org/10.1093/jac/dkt034
10. Maldonado NG, Takhar SS. Update on emerging infections: news from the Centers for Disease Control and Prevention. Update to the CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. Ann Emerg Med. 2013;61:91-5. http://dx.doi. org/10.1016/j.annemergmed.2012.10.014
11. Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis. 2014;14:220-6. http://dx.doi.org/10.1016/ S1473-3099(13)70693-5
12. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis. 2004;189:1497-505. http:// dx.doi.org/10.1086/383047
13. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18: pii: 20358.
14. Pandori M, Barry PM, Wu A, Ren A, Whittington WL, Liska S, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother. 2009;53:4032-4. Epub 2009 Jun 22. http://dx.doi.org/10.1128/AAC.00406-09
15. Martin I, Sawatzky P, Allen V, Hoang L, Lefebvre B, Mina N, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis. 2012;39:316-23. http:// dx.doi.org/10.1097/OLQ.0b013e3182401b69